Umeå biotech firm Vakona has secured funding from existing and new investors to advance its innovative acne treatment targeting skin microbiome imbalances. This financing will help complete product development and prepare for clinical trials, aided by academic collaboration.
Roger Folkhage has been appointed CEO of Umeå-based Medicvent, succeeding Erik Lindström. He aims to drive international expansion in workplace safety and healthcare, leveraging his sales experience. Folkhage recognizes the company's potential for growth and innovation in air pollutant evacuation solutions.
Umeå Biotech Incubator (UBI) has received 2.5 million SEK from Kempestiftelserna for 2026 to support research verification activities. This funding aids commercialization for researchers, solidifying UBI's position as a leading biotech incubator in Europe.
Nil Medical's "Vestpack" is undergoing clinical trials in Sweden and Finland, aiming to improve treatment experiences for pediatric cancer patients. The company seeks a Business & Sales Manager to support expansion and is exploring further opportunities internationally.
QureTech Bio AB has received a European patent for GmPcides, a new class of synthetic antibacterials effective against drug-resistant bacteria like MRSA. This patent guarantees protection until 2041.
Mucocort AB has been granted a patent in Australia for its medical technology innovation. The company has successfully developed M045A, an innovative mucoadhesive "patch" for the treatment of oral aphthous ulcers.
Lina Olsson, former CEO of HiloProbe, has been appointed Business Unit Manager at Prevas in Umeå, where she will build up the local operations in MedTech and Life Science. The technology consultant firm Prevas aims to build a strong local team and tailor services to community needs.
Tobias Tovedal, a UBI business coach, becomes CEO of Patient Safety Surveillance Solutions (P3S), a KI startup developing software for monitoring healthcare-associated injuries. His leadership aims to enhance patient safety through real-time data analysis and expansion to more hospitals in Sweden.
Umeå Biotech Incubator has been awarded SEK 14.6 million in excellence funding by Vinnova, reaffirming its status as an excellent incubator. This funding, designated for 2025-2029, supports startups' growth, emphasizing sustainability and gender equality in business development.
HILICON, based in Umeå, has achieved record turnover and significant market presence in chromatography within ten years. CEO Wen Jiang aims to launch new products in 2025, expand the premises, and in the long term double the turnover while maintaining a focus on innovation and tailored customer solutions.
MetaCurUm AB has received a SEK 1 million grant from the Swedish Innovation Agency Vinnova to advance its therapeutic antibody for prostate cancer toward clinical trials. The Vinnova funds will be used further to validate MetaCurUm's mechanism of action and product. MetaCurUm is collaborating with the Institute of Cancer Research in London and Professor Johan de Bono.
Four pilot projects will receive dedicated support to accelerate the commercialization of their specific biological product through BRIDGE Sweden. The projects, three Academic and one start-up, will set the standard, help to identify essential offerings and refine the approach at SciLife Lab’s DDD platform, Testa Center and Lund’s Stem Cell Center and pre-GMP facility.